Identification of three coagulins as MMP inhibitors from Withania coagulans Dunal fruits




MMP inhibitors, Withania Coagulan Dunal, Column chromatography, dot-blot assay, Coagulins


Introduction and Aim: W. coagulans Dunal has been reported to contain an array of bioactive compounds. The present investigation was carried out to investigate MMP inhibitory molecules from W. coagulans Dunal fruit.


Materials and Methods: Isolation of active principle compounds and anti-ChC activity from methanol extract of W. coagulans Dunal fruit were carried out using chromatographic techniques and dot-blot assay on X-ray film. Active principle compounds were identified by ESI MS, 1H, and 13C NMR spectroscopy. The Bioefficacy of compounds was assessed by in vitro solution assay and gelatin zymography.


Results: Dot blot assay of methanol extract of W. coagulans Dunal fruit exhibited inhibitory activity against ChC (Clostridium histolyticum collagenase). Bioactivity assay guided chromatographic fractionation revealed the presence of five compounds out of which three were tentatively identified as Coagulin-H, Coagulin-L, and Coagulin-O by ESI MS, 1H, and 13C NMR spectroscopy. In vitro solution assay revealed Coagulin-H exhibits the highest MMP-2 and MMP-9  inhibitory activity. Coagulin-L and Coagulin-O exhibit 80.57 ± 2.1 % and 70.96 ± 2.8 % inhibitor activities against MMP-2 and 78.94 ± 3.6% and 63.15 ± 3.8% inhibitor activities against MMP-9 at 150 µg/ml respectively. In gel inhibition assay by gelatin zymography revealed that crude extracted residue of fruit exhibits dose-dependent inhibitory potential against MMPs of NIH3T3 fibroblast and HeLa cervical cells.


Conclusion: Our results advocate the anti-MMP potential of purified Coagulin-H, Coagulin-L, and Coagulin-O of W. coagulans Dunal fruits. These bioactive principles could be further investigated in detail for anti-cancer properties.

Author Biographies

Bhimrao V. Jaiwal

Department of Biochemistry, Ghulam Nabi Azad Art, Commerce and Science College, Barshitakli, Akola, 444001, Maharashtra, India

Department of Biochemistry, Dr. Babasaheb Ambedkar Marathwada University, Aurangabad, 431004, Maharashtra India

Faiyaz K. Shaikh

Centre for Biotechnology, Pravara Institutes of Medical Sciences (DU), Loni, 413736, Maharashtra, India

Ajit B. Patil

Department of Biochemistry, Ghulam Nabi Azad Art, Commerce and Science College, Barshitakli, Akola, 444001, Maharashtra, India

Raghavendra L. S. Hallur

Centre for Biotechnology, Pravara Institutes of Medical Sciences (DU), Loni, 413736, Maharashtra, India


Cabral-Pacheco, G. A., Garza-Veloz, I., Castruita-De la Rosa, C., Ramirez-Acuna, J. M., Perez-Romero, B. A., Guerrero-Rodriguez, J. F., et al., The roles of matrix metalloproteinases and their inhibitors in human diseases. Int. J. Mol. Sci. 2020; 21(24): 9739. DOI:

Chowdhury, A., Wei, B., Noonan, S., Stetler Stevenson, W. Preclinical development of recombinant human tissue inhibitor of metalloprotease 2 as a novel biologic therapy for cancer. The FASEB J. 2015; 29(S1): 945.16. DOI:

Vihinen, P., Kahari, V.M. Matrix metalloproteinase in cancer: prognostic markers and therapeutic targets. Int. J. Cancer 2002; 99: 157-166. DOI:

Kodate, M., Kasai, T., Hashirnoto, H., Yasumoto, K., Iwata, Y., Manabe, H. Expression of matrix metalloproteinase (gelatinase) in T1 adenocarcinoma of the lung. Pathol. Int. 1997; 47(7): 461-469. DOI:

Zeng, F. C., Cen, S., Tang, Z.Y., Kang, X. L. Elevated matrix metalloproteinase-9 expression may contribute to the pathogenesis of bladder cancer. Oncol. Lett. 2016; 11: 2213-2222. DOI:

Rempe, R. G., Hartz, A. M. S., Bauer, B.Matrix metalloproteinases in the brain and blood-brain barrier: versatile breakers and makers. J. Cereb. Blood Flow Metab. 2016; 36: 1481-1507. DOI:

Provenzano, M., Andreucci, M., Garofalo, C., Faga, T., Michael, A., Ielapi, N. et al., The Association of Matrix metalloproteinases with chronic kidney disease and peripheral vascular disease: A light at the end of the tunnel? Biomol. 2020; 10: 154. DOI:

Wojtowicz Praga, S.M., Dickson, R.B., Hawkins, M.J. Matrix metalloproteinase inhibitors. Invest. New Drugs. 1997; 15: 61-75. DOI:

Nelson, A. R., Fingleton, B., Rothenberg, M. L., Matrisian, L. M. Matrix metalloproteinases: Biologic activity and clinical implications. J. Clin. Oncol. 2000; 18: 1135-1135. DOI:

Ferdinando, M. Natural Bio-drugs as matrix metalloproteinase inhibitors: New perspectives on the horizon? Recent Pat. Anticancer Drug Discov. 2006; 1: 91-103.

Hopkins, A. L., Groom, C. R. The druggable genome. Nat. Rev. Drug Discov. 2002: 1(9): 727-730. DOI:

Wong, E., Cohen, T., Romi, E., Levin, M., Peleg, Y., Arad, U. et al., Harnessing the natural inhibitory domain to control TNFA converting enzyme (TACE) activity in vivo. Sci. Rep. 2016; 6: 35598. DOI:

Mannello, F. Natural Bio-Drugs as Matrix Metalloproteinase Inhibitors: New Perspectives on the Horizon? Recent Patents on Anti-Cancer Drug Discov. 2006; 1: 91. DOI:

Gupta, V., Keshari, B.B., Withania Coagulans Dunal. (Paneer Doda): A Review. Int. J. Ayurved. Herbal Med. 2013; 3: 1330-1336.

Salwaan, C., Singh, A., Mittal, A., Singh, P. Investigation of the pharmacognostical, phytochemical and antioxidant studies of plant Withania coagulans Dunal. J. Pharmacog. Phytochem. 2012; 1(3): 32-39.

Maurya, R., Akansha, J. Chemistry and pharmacology of Withania coagulans: an Ayurvedic remedy. J. Pharma. Pharmacol. 2010; 62: 153-160. DOI:

Pichare, M.M., Kachole, M.S. Detection of electrophoretically separated protease inhibitors using X-ray film. J. Biochem. Biophys. Methods 1994; 28: 215-224. DOI:

Schröpfer, A., Kammerer, U., Kapp, M., Dietl, J., Feix, S., Anacker, J. Expression pattern of matrix metalloproteinases in human gynecological cancer cell lines. BMC Cancer. 2010; 10(1): 553. DOI:

He, X. H., Li, J. J., Xie, Y. H., Tang, Y. T., Yao, G. F., Qin, W. X., et al., Altered gene expression profiles of NIH3T3 cells regulated by human lung cancer associated gene CT120. Cell Res. 2004; 14: 487-496. DOI:

Collette, T., Bellehumeur, C., Kats, R., Maheux, R., Mailloux, J., Villeneuve, M. et al., Evidence for an increased release of proteolytic activity by the EUTOPIC endometrial tissue in women with endometriosis and for involvement of matrix metalloproteinase-9. Hum. Reprod. 2004; 19(6): 1257-1264. DOI:

Kleiner, D.E., Stetler-Stevenson, W.G. Quantitative zymography: detection of pictogram quantities of gelatinases. Anal. Bio¬chem. 1994; 218: 325-329. DOI:

Bottomley, K. M., Johnson, W. H., Walter, D. S. Matrix metalloproteinase inhibitors in arthritis. J Enzyme Inhib. 1998; 13(2): 79-101. DOI:

Rahman, A.U.,Choudhary, M. I., Yousaf, M., Gul, W., Qureshi, S. New Withanolides from Withania coagulans. Chem. Pharm. Bull. 1998b; 46(12): 1853-1856. DOI:

Chowdhury, A.A. Diverse Role of MMP-2 and MMP-9 in the Onset of Alzheimer Disease and Cancer. Austin Neurol. Neurosci. 2016; 1: 1013.

Rah, B., Amin, H., Yousuf, K., Khan, S., Jamwal, G., Mukherjee, D. et al. A novel MMP-2 inhibitor 3-Azidowithaferin A (3-azidowa) abrogates cancer cell invasion and angiogenesis by modulating extracellular par-4. PLOS One. 2012; 7: 44039. DOI:




How to Cite

V. Jaiwal B, K. Shaikh F, B. Patil A, L. S. Hallur R. Identification of three coagulins as MMP inhibitors from Withania coagulans Dunal fruits. Biomedicine [Internet]. 2022 Nov. 14 [cited 2022 Nov. 27];42(5):929-37. Available from:



Original Research Articles

Plum Analytics